Back to Stakeholders

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

Academic Research

0 papers

Published Papers

0

Trial Involvement

4

Distinct Focus Topics

0

Latest Publication

Unknown

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Ketamine + Esketamine Services

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Service Modalities

Ketamine Infusion TherapyEsketamine (Spravato)

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

2

Collaborated Trials

2